BTK pathway示意图 上期说到BTK抑制剂治疗血肿有一个很重要的局限性就是副作用/不耐受 首先是ibrutinib,从其3个主要的CLL临床试验(RESONATE、RESONATE-2、PCYC1102/1103)来看(N=330),停药率大约为38%,其中因为AE停药的占样本量的11%。前线用药的患者5年停药率为41%,大多数都是因为AE停药的。现在越来越多的...
[13] Castillo JJ, Treon SP, Davids MS, Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer J. 2016 Jan-Feb;22(1):34-9. [14] Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. (2002) The protein kinase complement of the human genome...
摘要:布鲁顿酪氨酸激酶(ＢＴＫ)是Ｂ细胞受体(ＢＣＲ)信号传导的关键组分ꎬ并且作为体内Ｂ细胞增殖和细胞存活的重要调节剂起作用ꎮ本文综述了布鲁顿酪氨酸激酶信号通路的传导过程ꎬ包括主要的Ｂ细胞受体信号通路与其他通路ꎮ布鲁顿酪氨酸激酶基因缺陷会引发免疫缺陷Ｘ连锁性丙种球蛋白血症(ＸＬＡ)ꎬ而布鲁顿酪氨酸...
参考文献：1Valla K, Flowers CR, Koff JL. Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Expert OpinInvestig Drugs, 2018; 27(6): 513-522.2Valla K, Flowers CR, Koff JL. Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Expert OpinInvestig Drugs, 2018; 27(6...
Zanubrutinib ameliorates experimental idiopathic inflammatory myopathy-associated interstitial lung disease by BTK/NF-κB signaling pathway Article 作者:Zhou, Honggang;Li, Xiaohe;Liu, Jing;Ai, Xiaoyu;Liu, Zhichao;Jiao, Ran;Chai, Dan;Liu, Yuming;Liu, Zhigang;Li, Wenqi;Yang, Zhongyi;Meng, Lingxin...
泛素蛋白酶体途径(Ubiquitin-proteasome Pathway),是所有真核生物体内最重要的蛋白质降解途径,有关研究于2004年获得了诺贝尔化学奖。PROTAC靶向技术,巧妙的利用了泛素蛋白酶体途径介导的蛋白降解这个机体用来调节细胞内蛋白水平与功能的重要机制,是一项突破性的发明。与传统的小分子抑制剂相比,基于PROTAC技术的蛋白降解剂...
产品货号 产品规格 目录价 55355ES08 5 mg 425.00 55355ES25 25 mg 1255.00 批量采购,请点击询价 产品说明书 FAQ COA 已发表文献 产品性质 英文别名(English Synonym) ACP-196 中文名称(Chinese Name) 阿可替尼 靶点(Target) BTK 通路(Pathway) Angiogenesis ...
36.neri,a.等人,“口服蛋白激酶cβ抑制剂恩扎妥林(ly317615)通过akt路径遏制信号传导,抑制多发性骨髓瘤细胞系的增殖并诱导细胞凋亡(theoralprotein-kinasecbetainhibitorenzastaurin(ly317615)suppressessignallingthroughtheaktpathway,inhibitsproliferationandinducesapoptosisinmultiplemyelomacelllines)”,《白血病和淋巴瘤(leuk...
Btk is a positive regulator in the TREM⁃1 / DAP12 signaling pathway [ J] . Blood, 2011, 118 (4) :936⁃945.Ormsby T, Schlecker E, Ferdin J, Tessarz AS, Angelisova P, Koprulu AD, et al. Btk is a positive regulator in the TREM-1/DAP12 signaling pathway. Blood. 2011;118(4...
It serves as a binding site for the SH2 domain ofPLCG2, which is a key downstream effector molecule involved in calcium signaling and activation of the protein kinase C (PKC) pathway. Y551 is located within the catalytic domain and is autophosphorylated upon activation of BTK. It provides ...